Data Registry of Multisystem Inflammatory Syndrome in Children

Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe post-infectious complication of SARS-CoV-2 with variable presentation and outcomes. Limited data exist from resource-limited regions. The aim of this research was to describe the clinical characteristics, laboratory findings, treatment approaches, and outcomes of children diagnosed with MIS-C. Methods: A retrospective cohort was conducted on 30 children fulfilling the CDC criteria for MIS-C. Data were retrieved from hospital records, including demographics, clinical features, laboratory parameters, management, and outcomes. Results: The mean age was 49.1 ± 49.7 months (median = 36 months); males constituted 70%. Rural residence was predominant (63.3%). All patients presented with fever; 56.7% developed shock, 36.7% had elevated troponin, and 26.7% showed coronary changes. Gastrointestinal symptoms were frequent—vomiting (70%), abdominal pain (40%), and diarrhea (33.3%)—while mucocutaneous signs occurred in 60%. Respiratory involvement was seen in 80% and neurological manifestations in 33.3%. Inflammatory markers were significantly elevated (CRP 87.3 ± 47.5 mg/L, ESR 70.9 ± 23.5 mm/hr, D-dimer 6.15 ± 4.87 ng/mL). Mortality was 30%. Poor outcomes were significantly associated with younger age (p = 0.003), lower weight (p = 0.006), erythema/edema of extremities (p = 0.034), abdominal pain (p = 0.034), shock (p = 0.002), renal failure (p = 0.006), and disturbed consciousness (p < 0.001). Conclusion: MIS-C in this cohort predominantly affected younger male children and was frequently complicated by shock and cardiac dysfunction. The 30% mortality rate higher than international figures likely reflects delayed diagnosis and limited intensive care access.